DB:4OD

Stock Analysis Report

Executive Summary

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Risks

  • Odonate Therapeutics has significant price volatility in the past 3 months.
  • Odonate Therapeutics is covered by less than 3 analysts.

Share Price & News

How has Odonate Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

DB:4OD

2.2%

DE Pharmaceuticals

0.2%

DE Market


1 Year Return

115.4%

DB:4OD

-9.7%

DE Pharmaceuticals

-10.0%

DE Market

4OD outperformed the Pharmaceuticals industry which returned -9.9% over the past year.

4OD outperformed the Market in Germany which returned -10.4% over the past year.


Share holder returns

4ODIndustryMarket
7 Day0%2.2%0.2%
30 Day11.5%6.6%-3.3%
90 Day78.4%10.9%-3.9%
1 Year115.4%115.4%-6.6%-9.7%-7.1%-10.0%
3 Yearn/a-11.0%-18.6%11.3%1.7%
5 Yearn/a33.2%11.3%25.8%8.4%

Price Volatility Vs. Market

How volatile is Odonate Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Odonate Therapeutics undervalued based on future cash flows and its price relative to the stock market?

5.55x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Odonate Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Odonate Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Odonate Therapeutics is loss making, we can't compare its value to the DE Pharmaceuticals industry average.

Odonate Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Odonate Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Odonate Therapeutics is overvalued based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Odonate Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

34.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Odonate Therapeutics is high growth as no revenue estimate data is available.

Odonate Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Odonate Therapeutics's revenue growth to the Germany market average as no estimate data is available.

Odonate Therapeutics's earnings growth is expected to exceed the Germany market average.

Odonate Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Odonate Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Odonate Therapeutics performed over the past 5 years?

-80.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Odonate Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Odonate Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Odonate Therapeutics's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Odonate Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Odonate Therapeutics has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Odonate Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Odonate Therapeutics's financial position?


Financial Position Analysis

Odonate Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Odonate Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Odonate Therapeutics has no debt.

Odonate Therapeutics has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Odonate Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Odonate Therapeutics has sufficient cash runway for 2.3 years based on current free cash flow.

Odonate Therapeutics has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 97.1% each year.


Next Steps

Dividend

What is Odonate Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Odonate Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Odonate Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Odonate Therapeutics has not reported any payouts.

Unable to verify if Odonate Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Odonate Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Odonate Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Kevin Tang (52yo)

6.6yrs

Tenure

US$1

Compensation

Mr. Kevin C. Tang has been the Chairman and Chief Executive Officer at Odonate Therapeutics, Inc. since 2013. Mr. Tang has experience evaluating, creating and building biotechnology companies that are focu ...


CEO Compensation Analysis

Kevin's remuneration is lower than average for companies of similar size in Germany.

Kevin's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.9yrs

Average Tenure

52yo

Average Age

The average tenure for the Odonate Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.7yrs

Average Tenure

54yo

Average Age

The average tenure for the Odonate Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Odonate Therapeutics individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$8,786,99128 Jun 19
Tavistock Life Sciences
EntityCompany
Shares384,615
Max PriceUS$22.85
BuyUS$439,35528 Jun 19
Jeffrey Vacirca
EntityIndividual
Role
Vice Chairman
Vice Chairman
Shares19,231
Max PriceUS$22.85
BuyUS$17,574,00528 Jun 19
Tang Capital Management, LLC
EntityCompany
Shares769,231
Max PriceUS$22.85
BuyUS$1,167,24619 Jun 19
Tang Capital Management, LLC
EntityCompany
Shares50,000
Max PriceUS$24.06
BuyUS$1,841,13710 Jun 19
Tang Capital Management, LLC
EntityCompany
Shares76,308
Max PriceUS$24.65
BuyUS$2,076,24105 Jun 19
Tang Capital Management, LLC
EntityCompany
Shares93,692
Max PriceUS$23.22
BuyUS$2,273,58811 Mar 19
Tang Capital Management, LLC
EntityCompany
Shares140,000
Max PriceUS$16.84
BuyUS$45,04807 Mar 19
Jeffrey Vacirca
EntityIndividual
Role
Vice Chairman
Vice Chairman
Shares3,000
Max PriceUS$15.02
BuyUS$729,38231 Dec 18
Tang Capital Management, LLC
EntityCompany
Shares63,700
Max PriceUS$12.23
BuyUS$1,453,96427 Dec 18
Tavistock Life Sciences
EntityCompany
Shares125,000
Max PriceUS$11.81
BuyUS$662,50826 Dec 18
Tang Capital Management, LLC
EntityCompany
Shares60,000
Max PriceUS$12.08
BuyUS$516,12518 Dec 18
Tang Capital Management, LLC
EntityCompany
Shares40,000
Max PriceUS$13.37
BuyUS$274,71814 Dec 18
Tang Capital Management, LLC
EntityCompany
Shares20,000
Max PriceUS$13.88
BuyUS$259,59110 Dec 18
Tang Capital Management, LLC
EntityCompany
Shares20,000
Max PriceUS$13.14
BuyUS$42,42629 Nov 18
Tang Capital Management, LLC
EntityCompany
Shares3,063
Max PriceUS$13.85
BuyUS$228,40127 Nov 18
Tang Capital Management, LLC
EntityCompany
Shares16,937
Max PriceUS$13.61
BuyUS$130,53806 Nov 18
Tang Capital Management, LLC
EntityCompany
Shares10,000
Max PriceUS$13.05
BuyUS$134,73330 Oct 18
Tang Capital Management, LLC
EntityCompany
Shares10,235
Max PriceUS$13.92
BuyUS$346,43526 Oct 18
Tavistock Life Sciences
EntityCompany
Shares26,824
Max PriceUS$12.92
BuyUS$536,63725 Oct 18
Tang Capital Management, LLC
EntityCompany
Shares39,765
Max PriceUS$13.87
BuyUS$659,56101 Oct 18
Tang Capital Management, LLC
EntityCompany
Shares40,000
Max PriceUS$16.64
BuyUS$672,34626 Sep 18
Tang Capital Management, LLC
EntityCompany
Shares40,000
Max PriceUS$17.28
BuyUS$1,497,33721 Sep 18
Tang Capital Management, LLC
EntityCompany
Shares90,000
Max PriceUS$17.39
BuyUS$126,80023 Aug 18
Tang Capital Management, LLC
EntityCompany
Shares7,505
Max PriceUS$16.90

Ownership Breakdown


Management Team

  • Kevin Tang (52yo)

    Chairman & CEO

    • Tenure: 6.6yrs
    • Compensation: US$1.00
  • Michael Hearne (56yo)

    CFO & Principal Accounting Officer

    • Tenure: 0.8yrs
  • Thomas Wei (43yo)

    Chief Scientific Officer

    • Tenure: 0.8yrs
  • Stewart Kroll (60yo)

    Chief Development Officer

    • Tenure: 2.8yrs
  • John Lemkey (38yo)

    Chief Operating Officer

    • Tenure: 0.8yrs
    • Compensation: US$849.92k
  • Joseph O’Connell (65yo)

    Chief Medical Officer

    • Tenure: 1.9yrs
    • Compensation: US$1.45m
  • Steven Pfeiffer (43yo)

    Vice President of Technical Operations

    • Tenure: 3.0yrs

Board Members

  • Kevin Tang (52yo)

    Chairman & CEO

    • Tenure: 6.6yrs
    • Compensation: US$1.00
  • George Tidmarsh (59yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: US$365.57k
  • Laura Douglass (54yo)

    Independent Director

    • Tenure: 0.7yrs
    • Compensation: US$472.09k
  • Aaron Davis (41yo)

    Independent Director

    • Tenure: 2.7yrs
  • Craig Johnson (57yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$390.57k
  • Robert Rosen (63yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$365.57k
  • Jeff Vacirca (50yo)

    Vice Chairman

    • Tenure: 3.1yrs
    • Compensation: US$390.57k

Company Information

Odonate Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Odonate Therapeutics, Inc.
  • Ticker: 4OD
  • Exchange: DB
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.084b
  • Listing Market Cap: US$977.185m
  • Shares outstanding: 32.19m
  • Website: https://www.odonate.com

Number of Employees


Location

  • Odonate Therapeutics, Inc.
  • 4747 Executive Drive
  • Suite 510
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4ODMUN (Boerse Muenchen)YesCommon StockDEEURDec 2017
ODTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2017
4ODDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2017

Biography

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinica ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 22:59
End of Day Share Price2019/08/06 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.